Biogen (BIIB): Tecfidera Sales Could Be Weak - Baird

Baird analyst, Brian Skorney, reiterated his Neutral rating on shares of Biogen (NASDAQ: BIIB) ahead of earnings. The analyst is expecting earnings to be generally in line but revenues from Tecfidera to be weak.

Biogen is set to report 4Q16 earnings on Thursday, January 26 BMO. There is no change to estimates or the price target of $309.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $280.35 yesterday.

You May Also Be Interested In

• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
• Nlight (LASR) Reiterated at Buy by Stifel: Sell-off is a 'Buying Opportunity'